ال پيچر	JF ,	2 1	2004	OFFICE	
\overline{x}				957	

TRANSMITTAL LETTER (General - Patent Pending)

Docket No. 01200/1/US

In Ro Adelication Of: Danchen Gao et al.

Serial No. 10/741,530 Filing Date

Examiner

Group Art Unit

December 18, 2003

Unknown

1616

Title: ACCEPTABLY NON-HYGROSCOPIC FORMULATION INTERMEDIATE COMPRISING A HYGROSCOPIC DRUG

TO THE COMMISSIONER FOR PATENTS:

Transmitted herewith is:

Information Disclosure Statement; Form 1449; Cited References (6); Itemized Postcard.

in the above identified application.

- No additional fee is required.
- A check in the amount of

is attached.

The Director is hereby authorized to charge and credit Deposit Account No.

19-1025

as described below.

- Charge the amount of
- \boxtimes Credit any overpayment.
- Charge any additional fee required.

Pathuals

Dated: July 19, 2004

Patricia K. Fitzsimmons, Reg. No. 52,894 Pharmacia Corporation of Pfizer Inc. P.O. Box 1027

Chesterfield, Missouri 63006

314.274.1490

certify that this document and fee is being deposited with the U.S. Postal Service as chuly 19, 2004 first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Linda K. Cooper

Typed or Printed Name of Person Mailing Correspondence

(E)	Case 01200/1/US			
173	THE UNITED STATE	S PATENT AND TRADEMARK	<u>OFFICE</u>	
ACEMAN APPLICANT:	Danchen Gao et al.) GROUP ART UNIT:	1616	
SERIAL NO.:	10/741,530) CONFIRMATION NO.:	4628	
EXAMINER:	Unknown) ATTORNEY DOCKET NO.:	01200/1/US	
FILED:	December 18, 2003)		

TITLE:

ACCEPTABLY NON-HYGROSCOPIC FORMULATION INTERMEDIATE

COMPRISING A HYGROSCOPIC DRUG

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97 and 1.98

July 19, 2004

Commissioner of Patents Box 1450 Alexandria, VA 22313

Sir:

This Information Disclosure Statement is filed pursuant to 37 CFR 1.97 and 1.98 and MPEP §609. Copies of the references listed on the attached Form PTO-1449 are enclosed herein.

Each item contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. No fee is required under §1.97.

Please charge any fee required by §1.97 to Deposit Account No. 19-1025.

Respectfully submitted,

Patricia K. Fitzsimmons Attorney for Applicants Registration No. 52,894

(314) 274-1490

Pharmacia Corporation of Pfizer Inc. Global Patent Department Post Office Box 1027 St. Louis, MO 63006

		, ,			Docket Number (Optional)		Application Number			
INFORMATION DISCLOSURE CITATION				01200/1/US 10/741,530 Applicant(s)						
/ 01	(Use several sheets if necessary)				Danchen Gao et al. Filing Date Group Art Unit					
ح الل	5)			December 18, 2003 1616						
2	ZUZ	U.S. PATENT DOCUMENTS								
EXAMINER INCLASERS	ARRACE	DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
	3.	4,835,187	05/30/1989	Reuter	et al. 	514/570		06/15/1987		
	2.	5,582,837	12/10/1996	Shell		424/451		05/30/1995		
	3.	5,939,100	08/17/1999	Albrechtsen et al.		424/489		10/03/1994		
	4.	Pub. No.US2002/0143058	10/03/2002	Safadi et al.		514/557		01/24/2001		
							_			
									ā	
<u></u>										
				FOREIG	N PATENT DOCUMENTS					
	REF	DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS Translation YES S		NO NO	
	5.	WO 01/72703	10/04/2001	PCT		323/58		~)	
			-							
	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)									
		PCT Search Report, 4 pgs.								
EXAMINE	XAMINER DATE CONSIDERED									
XAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and ot considered. Include copy of this form with next communication to applicant.										